1. Scrip
  2. >>Archive

Myriad Genetics' M&A Buys Into Protein-Based Testing

Oncology oriented Myriad Genetics is investing $25 million in Crescendo Bioscience, a developer of molecular diagnostics for inflammatory disorders. The deal aims at more than a financial return: it includes a 3-year option to acquire Crescendo. That would strengthen Myriad's protein-based test development capabilities. Adding Crescendo to the fold would be consistent with Myriad's focus on service-based offerings -- often a predicate for success in commercializing high-value diagnostics.

In keeping with its goal of diversifying revenues to go beyond oncology, Myriad Genetics Inc. is investing $25 million in the success of Crescendo Bioscience Inc., a developer of molecular diagnostics for rheumatoid arthritis (RA) and other inflammatory disorders. [See Deal] The financing adds to a just-closed $31 million Series C financing by Crescendo, which launched its first test, Vectra DA, for monitoring RA disease activity, last November. That round was led by Aeris Capital and included existing investors Mohr Davidow Ventures, Kleiner Perkins Caufield & Byers, and others. [See Deal]

For Myriad, the deal aims at much more than obtaining a financial return. Structured as long-term debt, it includes a three-year option to acquire Crescendo at a multiple of revenues...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.